Literature DB >> 11888880

Staging laparoscopy for potentially resectable noncolorectal, nonneuroendocrine liver metastases.

M D'Angelica1, W Jarnagin, R Dematteo, K Conlon, L H Blumgart, Y Fong.   

Abstract

BACKGROUND: Carefully selected patients with noncolorectal, nonneuroendocrine (NCNN) liver metastases may benefit from hepatic resection. The incidence of occult unresectable disease and the possible benefits of staging laparoscopy in these patients are not known.
METHODS: From December 1997 to July 2000, staging laparoscopy was performed in 30 consecutive patients with NCNN metastases before planned open exploration and resection. Demographics, extent of preoperative imaging, operative and postoperative findings, and factors associated with laparoscopic identification of unresectable disease were analyzed.
RESULTS: Twenty-four patients (80%) had a complete laparoscopic examination, and 23 had laparoscopic ultrasonography. All patients underwent preoperative computed tomography or magnetic resonance imaging, and 21 (70%) patients had 2 or more preoperative radiological studies. Overall, nine patients had unresectable disease, six of whom were identified by laparoscopy. Of the remaining 24 patients believed to have resectable disease at laparoscopy, 21 went on to a potentially curative procedure. Laparoscopy did not identify irresectability because of vascular involvement in three patients. Laparoscopy added a median of 30 minutes of operative time to those patients going on to laparotomy.
CONCLUSIONS: Laparoscopy identified the majority of patients with occult unresectable disease, improved resectability, and should be routine in patients being considered for potentially curative hepatic resection.

Entities:  

Mesh:

Year:  2002        PMID: 11888880     DOI: 10.1007/bf02557375

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  5 in total

1.  Virally-directed fluorescent imaging (VFI) can facilitate endoscopic staging.

Authors:  P S Adusumilli; D P Eisenberg; B M Stiles; K J Hendershott; S F Stanziale; M-K Chan; M Hezel; R Huq; V W Rusch; Y Fong
Journal:  Surg Endosc       Date:  2006-01-30       Impact factor: 4.584

2.  The impact of 18F-FDG PET/CT in patients with liver metastases.

Authors:  Siew C Chua; Ashley M Groves; Irfan Kayani; Leon Menezes; Svetislav Gacinovic; Yong Du; Jamshed B Bomanji; Peter J Ell
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-08-23       Impact factor: 9.236

3.  Liver resection for non-colorectal, non-neuroendocrine metastases: analysis of a multicenter study from Argentina.

Authors:  J Lendoire; M Moro; O Andriani; J Grondona; O Gil; G Raffin; J Silva; R Bracco; G Podestá; C Valenzuela; O Imventarza; J Pekolj; E De Santibañes
Journal:  HPB (Oxford)       Date:  2007       Impact factor: 3.647

4.  Diagnostic laparoscopy in the evaluation of the viral hepatitis patient with potentially resectable hepatocellular carcinoma.

Authors:  Eunjie K Klegar; Stuart G Marcus; Elliot Newman; Spiros P Hiotis
Journal:  HPB (Oxford)       Date:  2005       Impact factor: 3.647

5.  Liver resection for non-colorectal, non-carcinoid, non-sarcoma metastases: a multicenter study.

Authors:  Guillaume Martel; Jeff Hawel; Janelle Rekman; Kristopher P Croome; Kimberly Bertens; Fady K Balaa; Roberto Hernandez-Alejandro
Journal:  PLoS One       Date:  2015-03-26       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.